新媒网 · 跨境数据社区

✨ Let’s talk about iron deficiency ✨ We are inviting women aged 18–35 to take part in a clinical trial on iron deficiency. 🙋‍♀️ Help us advance women's health — and receive up to $150 for your time. ✨ Spots are limited — reach out today to see if you qualify! 💌

🌿 Explore who can join medical marijuana trials and what to expect.

🌿 Explore who can join medical marijuana trials and what to expect.

Join Our Clinical Research Trial Exploring Fatty Liver Disease We are conducting a clinical research trial to test an investigational medicine for people with a liver condition known as metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. This study aims to determine how effective and safe this investigational medicine is for treating MASH. What is Metabolic Dysfunction-Associated Steatohepatitis (MASH)? MASH is a type of liver disease where fat builds up in the liver, leading to inflammation and damage. This can cause fibrosis, which is the scarring of liver tissue. Over time, if left untreated, it can lead to more serious liver issues. Key Facts About Liver Disease • The Liver's Role: Your liver is vital for digestion, detoxifying your blood, and storing energy. • MASH: This condition occurs when the liver stores too much fat, causing inflammation and scarring. • Symptoms: Many people with MASH might not have symptoms initially, but over time it can lead to fatigue, pain in the upper right abdomen, and other complications. Who Can Participate? You may be eligible to join our clinical research trial if you meet the following criteria: • You are a male or non-pregnant female between the ages of 18 and 75. • You have a Body Mass Index (BMI) between 25 and 50 kg/m². • You are pre-diabetic, have Type 2 Diabetes, high blood pressure, and / or high cholesterol. Who Cannot Participate? You are not eligible for this study if you: • Have another chronic liver disease. • Have a history or current evidence of cirrhosis. • Have type 1 diabetes. Why Participate? By participating in this clinical research trial, you will be contributing to important research investigating treatments for MASH. What's in It for You? • Free Fibroscan: Pain-free and fast: No needles, no stress. Precise insights: Detects liver stiffness and fat buildup. • Travel Reimbursement: Worried about the cost of getting to our clinic? We’ve got you covered for reasonable travel costs. How to Apply: To determine your eligibility for this clinical research trial, please fill out our online eligibility form.

Join Our Clinical Research Trial Exploring Fatty Liver Disease We are conducting a clinical research trial to test an investigational medicine for people with a liver condition known as metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. This study aims to determine how effective and safe this investigational medicine is for treating MASH. What is Metabolic Dysfunction-Associated Steatohepatitis (MASH)? MASH is a type of liver disease where fat builds up in the liver, leading to inflammation and damage. This can cause fibrosis, which is the scarring of liver tissue. Over time, if left untreated, it can lead to more serious liver issues. Key Facts About Liver Disease • The Liver's Role: Your liver is vital for digestion, detoxifying your blood, and storing energy. • MASH: This condition occurs when the liver stores too much fat, causing inflammation and scarring. • Symptoms: Many people with MASH might not have symptoms initially, but over time it can lead to fatigue, pain in the upper right abdomen, and other complications. Who Can Participate? You may be eligible to join our clinical research trial if you meet the following criteria: • You are a male or non-pregnant female between the ages of 18 and 75. • You have a Body Mass Index (BMI) between 25 and 50 kg/m². • You are pre-diabetic, have Type 2 Diabetes, high blood pressure, and / or high cholesterol. Who Cannot Participate? You are not eligible for this study if you: • Have another chronic liver disease. • Have a history or current evidence of cirrhosis. • Have type 1 diabetes. Why Participate? By participating in this clinical research trial, you will be contributing to important research investigating treatments for MASH. What's in It for You? • Free Fibroscan: Pain-free and fast: No needles, no stress. Precise insights: Detects liver stiffness and fat buildup. • Travel Reimbursement: Worried about the cost of getting to our clinic? We’ve got you covered for reasonable travel costs. How to Apply: To determine your eligibility for this clinical research trial, please fill out our online eligibility form.

Join Our Clinical Research Trial Exploring Fatty Liver Disease We are conducting a clinical research trial to test an investigational medicine for people with a liver condition known as metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. This study aims to determine how effective and safe this investigational medicine is for treating MASH. What is Metabolic Dysfunction-Associated Steatohepatitis (MASH)? MASH is a type of liver disease where fat builds up in the liver, leading to inflammation and damage. This can cause fibrosis, which is the scarring of liver tissue. Over time, if left untreated, it can lead to more serious liver issues. Key Facts About Liver Disease • The Liver's Role: Your liver is vital for digestion, detoxifying your blood, and storing energy. • MASH: This condition occurs when the liver stores too much fat, causing inflammation and scarring. • Symptoms: Many people with MASH might not have symptoms initially, but over time it can lead to fatigue, pain in the upper right abdomen, and other complications. Who Can Participate? You may be eligible to join our clinical research trial if you meet the following criteria: • You are a male or non-pregnant female between the ages of 18 and 75. • You have a Body Mass Index (BMI) between 25 and 50 kg/m². • You are pre-diabetic, have Type 2 Diabetes, high blood pressure, and / or high cholesterol. Who Cannot Participate? You are not eligible for this study if you: • Have another chronic liver disease. • Have a history or current evidence of cirrhosis. • Have type 1 diabetes. Why Participate? By participating in this clinical research trial, you will be contributing to important research investigating treatments for MASH. What's in It for You? • Free Fibroscan: Pain-free and fast: No needles, no stress. Precise insights: Detects liver stiffness and fat buildup. • Travel Reimbursement: Worried about the cost of getting to our clinic? We’ve got you covered for reasonable travel costs. How to Apply: To determine your eligibility for this clinical research trial, please fill out our online eligibility form.

We invite you to learn more about our upcoming clinical research trial to evaluate the safety and effectiveness of an investigational medication for cardiovascular disease. Your participation could play a vital role in advancing medical research. Minimum eligibility requirements: ● ≥ 18 years of age with history of Atherosclerotic Cardiovascular Disease defined as Acute Coronary Syndrome or large artery ischemic stroke in the last 1-12 months ● Type 2 Diabetes ● Previous above ankle amputation ● Diagnosis of non-end stage Chronic Kidney Disease ● Current tobacco use By participating, you may: ● Gain access to investigational medication at no cost. ● Contribute to the advancement of medicine and potentially more effective therapeutics.

Help researchers fight the flu this fall

Help researchers fight the flu this fall

Living with elevated Triglycerides? Free of daily medications? You may be eligible for a research study. Compensation up to $9,120 upon study completion. Call 416-747-5246 or Toll Free: 1-833-879-2774 If high triglycerides are detected, you could be considered for an exclusive clinical trial offering advanced care and treatment at no cost to you!

Parents of children aged 6-12, enroll your child in a paid research study for eczema. Your child’s participation will aid in the development of new investigational treatments. Free study related health screenings and compensation may be provided. rebrand.ly/21874Eczema

Parents of children aged 6-12, enroll your child in a paid research study for eczema. Your child’s participation will aid in the development of new investigational treatments. Free study related health screenings and compensation may be provided. rebrand.ly/21874Eczema

🫘 Factors Governing the Erythropoietic Response to Intravenous Iron Infusion in Patients with Chronic Kidney Disease: A Retrospective Cohort Study by Chukwu, C.A., et al. (2023). Biomedicines, 11(9), 2417. ➡️ https://shorturl.at/q4XJf 👀 Views/Citations: 1774/1 📜 Abstract Background: Limited knowledge exists about factors affecting parenteral iron response. A study was conducted to determine the factors influencing the erythropoietic response to parenteral iron in iron-deficient anaemic patients whose kidney function ranged from normal through all stages of chronic kidney disease (CKD) severity. Methods: This retrospective cohort study included parenteral iron recipients who did not receive erythropoiesis-stimulating agents (ESA) between 2017 and 2019. The study cohort was derived from two groups of patients: those managed by the CKD team and patients being optimised for surgery in the pre-operative clinic. Patients were categorized based on their kidney function: Patients with normal kidney function [estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2] were compared to those with CKD stages 3–5 (eGFR < 60 mL/min/1.73 m2). Patients were further stratified by the type of iron deficiency [absolute iron deficiency (AID) versus functional iron deficiency (FID)]. The key outcome was change in hemoglobin (∆Hb) between pre- and post-infusion haemoglobin (Hb) values. Parenteral iron response was assessed using propensity-score matching and multivariate linear regression. The impact of kidney impairment versus the nature of iron deficiency (AID vs. FID) in response was explored. Results: 732 subjects (mean age 66 ± 17 years, 56% females and 87% White) were evaluated. No significant differences were observed in the time to repeat Hb among CKD stages and FID/AID patients. The Hb rise was significantly lower with lower kidney function (non-CKD and CKD1–2; 13 g/L, CKD3–5; 7 g/L; p < 0.001). When groups with different degrees of renal impairment were propensity-score matched according to whether iron deficiency was due to AID or FID, the level of CKD was found not to be relevant to Hb responses [unmatched (∆Hb) 12.1 vs. 8.7 g/L; matched (∆Hb) 12.4 vs. 12.1 g/L in non-CKD and CKD1–2 versus CKD3–5, respectively]. However, a comparison of patients with AID and FID, while controlling for the degree of CKD, indicated that patients with FID exhibited a diminished Hb response regardless of their level of kidney impairment. Conclusion: The nature of iron deficiency rather than the severity of CKD has a stronger impact on Hb response to intravenous iron with an attenuated response seen in functional iron deficiency irrespective of the degree of renal impairment.

Join a free clinical study

Research study 8541-646 Enrolling now. Receive up to $11,677. • Healthy Men and Women of Non-Childbearing Potential, age 18-65 • Available for 1 stay of 5 nights & 11 follow-up visits. • Compensation up to $11,677 for time and participation. • Refer A Friend & receive $400 per qualified referral. -------------------------------------------------------- Call or visit us online today! - (469) 914-8330 https://www.fortreaclinicaltrials.com/en-us/clinical-research/8541-646-pt-a-1s6d-11OPV

Chronic Kidney Disease for people of African heritage. Paid study now enrolling. You may qualify for this study if: ➡️ Age is 18 to 65. ➡️ You have APOL1 gene. ➡️ You have Chronic Kidney disease to Kidney Failure. Sign up for this study: https://www.remdavis.com/research-studies/#!/study/174

Chronic Kidney Disease for people of African heritage. Paid study now enrolling. You may qualify for this study if: ➡️ Age is 18 to 65. ➡️ You have APOL1 gene. ➡️ You have Chronic Kidney disease to Kidney Failure. Sign up for this study: https://www.remdavis.com/research-studies/#!/study/174

If you drink to excess more than once a week, you may qualify for a clinical trial for people who want to cut back or stop drinking altogether. Sign up now to learn more.

Do you want to contribute to the development of a new asthma treatment? Then sign up for a new research study here, by clicking the button below, and answer a short questionnaire.